PE20140646A1 - Vacuna de virus de dengue inactivado - Google Patents
Vacuna de virus de dengue inactivadoInfo
- Publication number
- PE20140646A1 PE20140646A1 PE2013002709A PE2013002709A PE20140646A1 PE 20140646 A1 PE20140646 A1 PE 20140646A1 PE 2013002709 A PE2013002709 A PE 2013002709A PE 2013002709 A PE2013002709 A PE 2013002709A PE 20140646 A1 PE20140646 A1 PE 20140646A1
- Authority
- PE
- Peru
- Prior art keywords
- dengue virus
- den
- inactivated dengue
- refers
- virus vaccine
- Prior art date
Links
- 229940023605 dengue virus vaccine Drugs 0.000 title 1
- 241000725619 Dengue virus Species 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 abstract 2
- 241000710829 Dengue virus group Species 0.000 abstract 1
- XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 abstract 1
- UUPHVTQVPXQGSK-UHFFFAOYSA-N [bis(hydroxymethyl)amino]methanol;methane Chemical compound C.OCN(CO)CO UUPHVTQVPXQGSK-UHFFFAOYSA-N 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 abstract 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910000160 potassium phosphate Inorganic materials 0.000 abstract 1
- 235000011009 potassium phosphates Nutrition 0.000 abstract 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 229930182490 saponin Natural products 0.000 abstract 1
- 150000007949 saponins Chemical class 0.000 abstract 1
- 239000001488 sodium phosphate Substances 0.000 abstract 1
- 229910000162 sodium phosphate Inorganic materials 0.000 abstract 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
SE REFIERE A UNA COMPOSICION INMUNOGENICA DEL VIRUS DE DENGUE QUE COMPRENDE: A) UNO O MAS VIRUS DE DENGUE INACTIVADOS PURIFICADOS DE DIFERENTES SEROTIPOS QUE PROVOCAN UNA RESPUESTA INMUNITARIA A CADA DEN-1, DEN-2, DEN-3 Y DEN-4; B) UN AGENTE REGULADOR TAL COMO FOSFATO DE SODIO, FOSFATO DE POTASIO O TRIS-(HIDROXI-METIL)-AMINO-METANO; C) UN TENSOACTIVO DE POLOXAMERO EN UNA CANTIDAD DE 0.001 A 1% P/V; D) UN ADYUVANTE TAL COMO HIDROXIDO DE ALUMINIO O FOSFATO DE ALUMINIO; Y E) UN COMPONENTE INMUNOESTIMULANTE ADICIONAL TAL COMO UNA EMULSION DE ACEITE Y AGUA, UN LIPOPOLISACARIDO, UNA SAPONINA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA PREPARACION LIOFILIZADA DEL VIRUS DE DENGUE INACTIVADO Y A UN METODO DE PREPARACION DEL MISMO
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490205P | 2011-05-26 | 2011-05-26 | |
| US201161570966P | 2011-12-15 | 2011-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20140646A1 true PE20140646A1 (es) | 2014-05-29 |
Family
ID=46148894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013002709A PE20140646A1 (es) | 2011-05-26 | 2012-05-25 | Vacuna de virus de dengue inactivado |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20140112953A1 (es) |
| EP (1) | EP2714076A1 (es) |
| JP (1) | JP2014515367A (es) |
| KR (1) | KR20140033171A (es) |
| CN (2) | CN103619349A (es) |
| AU (2) | AU2012260807B2 (es) |
| BR (1) | BR112013030236A2 (es) |
| CA (1) | CA2837145A1 (es) |
| CO (1) | CO6811814A2 (es) |
| EA (1) | EA201391515A1 (es) |
| IL (1) | IL229307A0 (es) |
| MX (1) | MX349119B (es) |
| PE (1) | PE20140646A1 (es) |
| PH (1) | PH12013502442A1 (es) |
| SG (1) | SG194950A1 (es) |
| WO (1) | WO2012160199A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3207936B1 (en) | 2014-11-18 | 2021-04-21 | Shionogi & Co., Ltd. | Stable peptide composition |
| US10086061B2 (en) * | 2015-03-11 | 2018-10-02 | The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research | Combination purified inactivated vaccine for flaviviruses |
| WO2017004567A1 (en) | 2015-07-02 | 2017-01-05 | PrimeVax Immuno-Oncology, Inc. | Compositions and methods for combination therapy with dengue virus and dendritic cells |
| US10765727B2 (en) | 2015-09-26 | 2020-09-08 | PrimeVax Immuno-Oncology, Inc. | Compositions and methods for producing dendritic cells |
| GB201522068D0 (en) * | 2015-12-15 | 2016-01-27 | Glaxosmithkline Biolog Sa | Dried composition |
| BE1024160B9 (fr) * | 2015-12-22 | 2017-12-06 | Glaxosmithkline Biologicals Sa | Formulation immunogène |
| WO2017210215A1 (en) * | 2016-05-31 | 2017-12-07 | The Government Of The United States Of America As Represented By The Secretary Of The Army | Zika virus vaccine and methods of production |
| CA3082779A1 (en) | 2016-11-16 | 2018-05-24 | PrimeVax Immuno-Oncology, Inc. | Combination immunotherapies for treatment of cancer |
| EP3565567A4 (en) * | 2017-01-04 | 2020-07-29 | Primevax Immuno-Oncology, Inc. | COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS |
| CN107140625A (zh) * | 2017-06-14 | 2017-09-08 | 中国海洋大学 | 一种利用植物油制备石墨烯薄膜的方法 |
| CA3080656A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| CN111615397B (zh) | 2017-11-03 | 2024-09-13 | 武田疫苗股份有限公司 | 寨卡疫苗和免疫原性组合物及其使用方法 |
| MX2020005554A (es) | 2017-11-30 | 2020-10-12 | Takeda Vaccines Inc | Vacunas y composiciones inmunogenas para zika y metodos para usarlas. |
| UA129245C2 (uk) | 2017-12-07 | 2025-02-26 | Мерк Шарп Енд Доум Елелсі | Склад вакцинної композиції від вірусу денге |
| US20230054318A1 (en) * | 2019-12-11 | 2023-02-23 | Ne1 Inc. | Personalized tumor vaccine and use thereof for cancer immunotherapy |
| BR112022015710A2 (pt) * | 2020-02-27 | 2022-09-27 | Takeda Vaccines Inc | Método para remover dna de célula hospedeira a partir da preparação de vírus |
| CN112546213A (zh) * | 2020-12-31 | 2021-03-26 | 中国医学科学院医学生物学研究所 | 一种制备新型冠状病毒疫苗的方法及针对其有效性的评价方法 |
| CN113750228B (zh) * | 2021-09-25 | 2024-02-20 | 大连理工大学 | 一种冷冻保护剂在铝佐剂中的应用 |
| CN115531529A (zh) * | 2022-09-16 | 2022-12-30 | 大连理工大学 | 一种冻干保护剂在含铝佐剂中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6254873B1 (en) * | 1995-04-17 | 2001-07-03 | The United States Of America As Represented By The Secretary Of The Army | Inactivated dengue virus vaccine |
| PL362964A1 (en) * | 2000-10-02 | 2004-11-02 | Glaxosmithkline Biologicals S.A. | Vaccine |
| EP1592440A4 (en) * | 2003-02-10 | 2007-07-11 | Elan Pharm Inc | IMMUNOGLOBULIN PREPARATION AND METHOD OF PRODUCING THE SAME |
| EP1766034B1 (en) * | 2004-05-21 | 2014-03-19 | Novartis Vaccines and Diagnostics, Inc. | Alphavirus vectors for influenza virus vaccines |
| CN101360821A (zh) * | 2005-11-21 | 2009-02-04 | 圣诺菲·帕斯图尔有限公司 | 重组病毒的稳定制剂 |
| SG10201913741YA (en) * | 2007-04-06 | 2020-03-30 | Takeda Vaccines Inc | Methods and compositions for live attenuated viruses |
| KR20110081824A (ko) * | 2008-09-29 | 2011-07-14 | 캐딜라 파마슈티클즈 리미티드 | 백신 보조제 |
| BRPI1011224A2 (pt) * | 2009-02-17 | 2016-03-15 | Glaxosmithkline Biolog Sa | vacina contra vírus da dengue inativado com adjuvante livre de alumínio |
| US9005633B2 (en) * | 2009-07-17 | 2015-04-14 | The United States Of America As Represented By The Secretary Of The Navy. | Psoralen-inactivated viral vaccine and method of preparation |
| US8557253B2 (en) * | 2009-10-07 | 2013-10-15 | Sanofi Pasteur Sa | Stabilizing excipient for inactivated whole virus vaccine |
-
2012
- 2012-05-25 KR KR1020137034545A patent/KR20140033171A/ko not_active Ceased
- 2012-05-25 WO PCT/EP2012/059879 patent/WO2012160199A1/en not_active Ceased
- 2012-05-25 CA CA2837145A patent/CA2837145A1/en not_active Abandoned
- 2012-05-25 CN CN201280031821.0A patent/CN103619349A/zh active Pending
- 2012-05-25 CN CN201710173241.XA patent/CN107050445A/zh active Pending
- 2012-05-25 EP EP12723216.3A patent/EP2714076A1/en not_active Withdrawn
- 2012-05-25 US US14/119,902 patent/US20140112953A1/en not_active Abandoned
- 2012-05-25 JP JP2014511908A patent/JP2014515367A/ja active Pending
- 2012-05-25 AU AU2012260807A patent/AU2012260807B2/en not_active Ceased
- 2012-05-25 MX MX2013013862A patent/MX349119B/es active IP Right Grant
- 2012-05-25 BR BR112013030236A patent/BR112013030236A2/pt not_active Application Discontinuation
- 2012-05-25 EA EA201391515A patent/EA201391515A1/ru unknown
- 2012-05-25 SG SG2013084298A patent/SG194950A1/en unknown
- 2012-05-25 PH PH1/2013/502442A patent/PH12013502442A1/en unknown
- 2012-05-25 PE PE2013002709A patent/PE20140646A1/es not_active Application Discontinuation
-
2013
- 2013-11-07 IL IL229307A patent/IL229307A0/en unknown
- 2013-11-26 CO CO13277999A patent/CO6811814A2/es unknown
-
2016
- 2016-08-05 AU AU2016210743A patent/AU2016210743A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012260807B2 (en) | 2016-05-12 |
| PH12013502442A1 (en) | 2018-03-21 |
| CA2837145A1 (en) | 2012-11-29 |
| CN103619349A (zh) | 2014-03-05 |
| WO2012160199A1 (en) | 2012-11-29 |
| SG194950A1 (en) | 2013-12-30 |
| US20140112953A1 (en) | 2014-04-24 |
| EP2714076A1 (en) | 2014-04-09 |
| BR112013030236A2 (pt) | 2016-12-06 |
| CN107050445A (zh) | 2017-08-18 |
| CO6811814A2 (es) | 2013-12-16 |
| IL229307A0 (en) | 2014-01-30 |
| JP2014515367A (ja) | 2014-06-30 |
| MX349119B (es) | 2017-07-12 |
| AU2016210743A1 (en) | 2016-08-25 |
| KR20140033171A (ko) | 2014-03-17 |
| MX2013013862A (es) | 2014-01-23 |
| EA201391515A1 (ru) | 2014-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20140646A1 (es) | Vacuna de virus de dengue inactivado | |
| MX347210B (es) | Vacunas combinadas para prevención de infecciones por virus porcino. | |
| AR093421A1 (es) | Composiciones, metodos y usos de construcciones de virus del dengue de serotipo-4 | |
| BR112015001313A2 (pt) | composições de vacina | |
| CO2018011355A2 (es) | Composiciones y métodos de vacunación contra virus de dengue en niños y adultos jóvenes | |
| AR064009A1 (es) | Metodo de inmunizacion contra los 4 serotipos del dengue | |
| PH12021550479A1 (en) | Dengue vaccine unit dose and administration thereof | |
| MX374519B (es) | Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas. | |
| EP2448410A4 (en) | TREATMENT AND PREVENTION OF INFECTIONS WITH THE DENGUE VIRUS | |
| UY32274A (es) | Pestivirus quimericos | |
| PE20151588A1 (es) | Vacuna contra el virus del dengue | |
| EA202090699A2 (ru) | Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения | |
| BR112019006802A2 (pt) | compostos e métodos para diagnóstico e tratamento de infecções virais | |
| CR20140189S (es) | Vacunas y metodos para crear una vacuna para inducir la inmunidad a todos los serotipos del virus del dengue | |
| BR112018068342A2 (pt) | vacina de vírus zika vivo atenuado | |
| CU20110219A7 (es) | Composiciones y métodos para administración de vacunas contra virus del dengue | |
| CO2019000214A2 (es) | Vacuna contra virus de bronquitis infecciosa | |
| MX2017003117A (es) | Particula tipo virus de flavivirus. | |
| MX2017009306A (es) | Vacuna contra la fiebre aftosa. | |
| BR112017004197A2 (pt) | composições de vacina contra doenças do vírus da dengue | |
| CA2915027A1 (en) | Compositions and methods for administration of vaccines against dengue virus | |
| BR112017013375A2 (pt) | composição de proteção solar cosmética | |
| BR112016002354A2 (pt) | composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit | |
| CL2013001877A1 (es) | Composicion inmunogenica que comprende un virus de diarrea viral bovina tipo 1b vivo modificado y un portador veterinario aceptable; vacuna que la comprende; y su uso para prevenir, tratar, manejar o aliviar uno o mas sintomas de una enfermedad causada por pestivirus. | |
| MX2016016746A (es) | Composiciones de vacuna con adyuvante dual, preparacion y usos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |